Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica , Deleção Cromossômica , Cromossomos Humanos Par 17 , Pulmão/patologia , Leucemia-Linfoma Linfoblástico de Células T Precursoras/diagnóstico , Adulto , Dor no Peito/patologia , Tosse/patologia , Análise Citogenética , Dispneia/patologia , Feminino , Humanos , Pulmão/diagnóstico por imagem , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Leucemia-Linfoma Linfoblástico de Células T Precursoras/diagnóstico por imagem , Leucemia-Linfoma Linfoblástico de Células T Precursoras/tratamento farmacológico , Leucemia-Linfoma Linfoblástico de Células T Precursoras/genética , Radiografia , Resultado do TratamentoRESUMO
Isolated myeloid sarcoma (MS) is a rare extramedullary presentation of acute myeloid leukemia (AML). Little is known about MS outcomes due to its rarity. A population-based analysis of MS using the Survival, Epidemiology, and End Results (SEER) database was performed. We identified 345 patients, aged 15 or older, diagnosed with isolated MS between 1973 and 2010. Overall survival (OS) was calculated and compared between MS and non-MS AML using the log-rank test. Survival was also evaluated based upon the primary site of disease presentation. The 3-year survival rate for MS (0.319; 95% confidence interval [CI]: 0.267-0.371) was greater than for non-MS AML (0.172; 95% CI: 0.168-0.175). There was variation in survival based on the site of involvement. The survival rates for isolated MS involving the pelvis/genitourinary organs, eyes/gonads and gastrointestinal mucosa appeared to be slightly improved when compared to primary sites of soft tissues, lymphatic/hematopoietic tissues or nervous system.
